Nifedipine reduces pressor responsiveness to angiotensin II in pregnant women. 1994

A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
Department of Obstetrics and Gynecology, University of Ancona, Italy.

OBJECTIVE We assessed the action of nifedipine on vascular reactivity to angiotensin II (AII) in pregnant women at risk for hypertension. METHODS We studied eleven pregnant women (28-32 weeks' gestation) who had shown a 20 mmHg increase in basal diastolic blood pressure at AII infusion rates < 10 ng/kg/min (Effective pressor dose, EPD), and were therefore considered at high risk for the subsequent development of pregnancy-induced hypertension, according to Gant. After the AII infusion was completed, we allowed the patients 4 hours of rest to avoid interactions with the first test, then administered 10 mg nifedipine, and after 30 minutes repeated the test. RESULTS In all the 11 women the EPD after nifedipine administration had significantly reverted to normal (paired t-test: p < 0.03). CONCLUSIONS The efficacy of nifedipine in reducing the pressor response to AII suggests the involvement of intracellular free calcium in the vascular response to pressor agents in pregnancy, and supports the use of this drug in the treatment of pregnancy-induced hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011249 Pregnancy Complications, Cardiovascular The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS. Cardiovascular Pregnancy Complications,Complications, Cardiovascular Pregnancy,Pregnancy, Cardiovascular Complications,Cardiovascular Pregnancy Complication,Complication, Cardiovascular Pregnancy,Pregnancies, Cardiovascular Complications,Pregnancy Complication, Cardiovascular
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
February 1983, American journal of obstetrics and gynecology,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
February 1983, American journal of obstetrics and gynecology,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
October 1992, American journal of obstetrics and gynecology,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
September 2010, American journal of hypertension,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
June 1974, Obstetrics and gynecology,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
October 1978, American journal of obstetrics and gynecology,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
September 1994, American journal of obstetrics and gynecology,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
November 1988, American journal of obstetrics and gynecology,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
December 1994, The Journal of clinical investigation,
A L Tranquilli, and C Conti, and B Rezai, and G G Garzetti, and C Romanini
July 2015, Critical care medicine,
Copied contents to your clipboard!